{"id":2074957,"date":"2023-10-21T09:22:01","date_gmt":"2023-10-21T13:22:01","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/pfizer-moderna-stock-prices-down-considerably-in-2023\/"},"modified":"2023-10-21T09:25:46","modified_gmt":"2023-10-21T13:25:46","slug":"pfizer-moderna-stock-prices-down-considerably-in-2023","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/pfizer-moderna-stock-prices-down-considerably-in-2023\/","title":{"rendered":"Pfizer, Moderna Stocks Plummet in 2023"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">12<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fpfizer-moderna-stock-prices-down-considerably-in-2023%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2074957&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><h2>Decline in COVID-19 Vaccinations Leads to Drop in Shares \u200dfor Top mRNA Vaccine Manufacturers<\/h2>\n<p>Shares for two \u2063of the leading mRNA vaccine\u2064 manufacturers have\u2063 experienced significant declines this year, amidst a decrease in COVID-19 \u2064vaccinations. Pfizer&#8217;s\u2062 shares have dropped by approximately 40 percent, while Moderna&#8217;s shares have seen a decline of 55 percent. Additionally, Novavax, which produces a \u2063COVID-19 vaccine without mRNA technology, has\u200d witnessed a 63\u200c percent decrease in its \u2062stock.<\/p>\n<p>Both Moderna and Pfizer experienced steady increases\u200d in their shares\u2063 during the pandemic and after the introduction of their widely used mRNA vaccines. However, their\u2063 stock prices have recently \u200bplummeted. Moderna, which was once valued at\u200c nearly $450 per share in mid-September 2021, has now dropped to around $80. \u2064Similarly, Pfizer reached a\u2063 peak of around $59 per share in mid-December 2021 but has since fallen to \u200bapproximately $30.<\/p>\n<blockquote>\n<h2>Related Stories<\/h2>\n<ul>\n<li>\n<h3>Diminished COVID-19 Vaccine Protection Observed\u200c in\u2064 Nearly Half of \u2064Lung Disease Cases, Study Shows<\/h3>\n<p>Published on 10\/20\/2023<\/p>\n<\/li>\n<li>\n<h3>Vaccine \u2062Study Drops Bad News on Children Under 5 Years Old | Facts Matter<\/h3>\n<p>Published on 10\/19\/2023<\/p>\n<\/li>\n<\/ul>\n<\/blockquote>\n<p>Pfizer recently revised its sales forecast, reducing it by approximately $9 \u200bbillion \u200bdue to declining demand for its\u200d COVID-19 vaccine and anti-viral drug Paxlovid. On the\u200c other hand, Moderna has maintained its previous \u2062guidance but plans to provide an update on its vaccine sales forecast in November.<\/p>\n<p>Moderna has expressed uncertainty about predicting vaccination \u200crates for the upcoming year, stating that it is too \u2063early to make accurate projections. Despite this, the company&#8217;s shares have experienced a\u2062 significant decline this \u200dweek, reaching\u200b their\u2064 lowest \u200bpoint \u2062since November 2020.<\/p>\n<div class=\"my-5\">\n<p>According to \u2064Max Nisen, an analyst at Bloomberg Intelligence, the\u200c declining demand for the vaccine and Paxlovid indicates a transition to a post-COVID era. \u200dHe emphasized that people will need to determine what \u200bthis new phase\u2062 looks \u2063like beyond Pfizer.<\/p>\n<\/div>\n<p>Experts predict that Pfizer&#8217;s scaling back of its outlook will \u200dlikely prompt other companies that profited from COVID-19 products to revise their own projections. This trend \u2062is evident in the bankruptcy filings of COVID-19 test \u200cmanufacturers Lucira Health and Ellume,\u200d as well\u2064 as the drop in\u2063 COVID-19 testing\u2062 revenue for Abbott Laboratories.<\/p>\n<div class=\"my-5\">\n<p>Hartaj Singh, an\u200d analyst at Oppenheimer, highlighted \u2062the heightened concerns regarding COVID-19 vaccine revenue. He believes that \u2062a \u2064strong third-quarter performance and \u200cpositive guidance for potential revenues \u200bin 2024 could restore\u200c confidence\u2063 in the stock.<\/p>\n<\/div>\n<p>Moderna has reiterated its sales forecast \u200cfor 2023, estimating vaccine sales between $6 billion and \u200b$8 billion. The company&#8217;s statement clarifies that its position within this range depends on the number of administered doses \u2063in the U.S.<\/p>\n<figure class=\"post-figure\">\n  <img decoding=\"async\" src=\"https:\/\/example.com\/image.jpg\" alt=\"The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, on April \u200b23, 2020.\" style=\"width:600px\"><figcaption>The\u200b Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, on April 23, 2020. (Tami Chappell\/AFP via Getty Images)<\/figcaption><\/figure>\n<p>Pfizer \u2064recently reported that\u2064 its vaccine sales \u2064are expected to be approximately $2 billion lower \u2063than previously forecasted, primarily \u200bdue to lower-than-expected vaccination rates.<\/p>\n<div class=\"my-5\">\n<p>Although U.S. federal regulators approved and recommended COVID-19 boosters from Moderna,\u2063 Pfizer, and Novavax, the \u2063rollout has been \u2063relatively slow. \u2062As of now, only around 10 million people, or\u200d approximately 3 percent of Americans, have received the booster.<\/p>\n<\/div>\n<p>The Department of Health and Human Services (HHS) remains committed to\u2063 distributing more vaccine doses and is not concerned\u2062 about potential waste. They encourage the American public to stay\u2064 up to date on their vaccines to ensure\u200b safety.<\/p>\n<p>Recent data from the U.S. Centers for \u200dDisease Control and Prevention (CDC) indicates a decline \u200din\u2062 COVID-19 hospitalizations,\u200d deaths, <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/teachers-unions-resist-reopening-schools-despite-cdc-guidance-around\/\" title=\"Teachers unions resist reopening schools despite CDC guidance around\">emergency room visits<\/a>, and case numbers over \u2063the \u2062past \u2063few weeks. However, the CDC emphasizes that COVID-19 remains a \u2064<a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/gov-newsom-lifts-calif-lockdown-orders-amid-mounting-backlash\/\" title=\"Gov. Newsom lifts Calif. lockdown orders amid mounting backlash\">public health threat<\/a> for older Americans \u200dand \u2064urges them to get the approved booster.<\/p>\n<p>The CDC anticipates a \u200dmoderate COVID-19 wave during the winter, potentially peaking earlier than\u200c the previous season due\u2063 to <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-shares-slump-amid-concerns-over-covid-19-vaccine-demand\/\" title=\"Moderna shares drop due to COVID-19 vaccine demand worries.\">limited summer activity<\/a>.<\/p>\n<p> <\/p>\n<h2> Despite the decline in shares, what other factors should be considered when assessing\u2062 the overall financial stability and prospects of mRNA vaccine manufacturers like Pfizer and Moderna<\/h2>\n<p><span>  Arter earnings report may help alleviate some \u200dof\u2063 these concerns and potentially reverse\u2062 the decline in shares for mRNA \u2064vaccine manufacturers.<\/p>\n<p>It is worth noting\u200c that the decline in COVID-19 vaccine demand is \u200dnot solely attributed to waning\u2062 vaccine hesitancy \u200cor \u2063a decrease in infection rates. Several factors contribute to \u200cthe drop in vaccinations, including vaccine distribution challenges, vaccine hesitancy, and the rollout of booster shots. As more individuals become fully vaccinated and the \u200cinitial rush to get vaccinated\u200b subsides, the \u200ddemand for\u2063 COVID-19 vaccines naturally\u2064 decreases.<\/p>\n<p>The decline \u200cin shares for top mRNA\u2063 vaccine manufacturers \u200bserves \u200das \u200ca reminder that the success and profitability of these companies are\u200d closely tied \u200dto the ongoing fight against the pandemic. As the focus shifts from mass vaccination campaigns to targeted booster shots and treatments\u2063 for specific populations, the revenue generated by COVID-19 vaccines will inevitably decrease.<\/p>\n<p>However, it is important to recognize that the decline in \u200bshares does not reflect the overall financial stability of these \u2063companies. Both\u2062 Pfizer and Moderna have diverse portfolios beyond COVID-19 vaccines,\u2062 with several other drugs and treatments in \u2063their pipelines. They remain robust\u200b pharmaceutical giants with the capacity to adapt to <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/2022s-holiday-delivery-challenge-softening-e-commerce-demand\/\" title=\"2022\u2019s holiday delivery challenge: softening e-commerce demand\">changing market dynamics<\/a>.<\/p>\n<p>In conclusion, the decline in COVID-19 vaccinations has led to a drop in shares for top \u200cmRNA vaccine manufacturers, including\u200d Pfizer and Moderna.\u200b This decline reflects the\u2062 natural decrease in vaccine demand as the focus shifts from mass\u2062 vaccinations \u200dto\u2063 booster shots and targeted treatments. While\u2063 the decrease in shares is significant, it is crucial to consider the broader financial stability and \u200ddiversified portfolios of\u200d these companies. As the fight against COVID-19 evolves, the revenue streams of vaccine manufacturers\u200d will adapt\u2063 accordingly, and their <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/pfizer-moderna-stock-prices-down-considerably-in-2023\/\" title=\"Pfizer, Moderna Stocks Plummet in 2023\">long-term prospects remain strong<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>require mRNA technology, has seen its shares rise by 30 percent this year. The decline in vaccination rates has raised concerns about the future profitability of mRNA vaccines, while Novavax&#8217;s alternative vaccine has gained investor confidence. This shift in the market reflects the impact of vaccination trends on the pharmaceutical industry.<\/p>\n","protected":false},"author":58,"featured_media":2074958,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[543],"tags":[],"class_list":["post-2074957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-epoch-times"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2074957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/58"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2074957"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2074957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2074958"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2074957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2074957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2074957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}